TLSI
TriSalus Life Sciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$3.89
+11.78%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.60
From 52W high−48.13%
Volume232072.00
Market cap$239.53M
P/E (TTM)—
P/S (TTM)5.3x
Div yield—
Key dataNov 4, 2026
Open
$3.60
From 52W high
−48.13%
Volume
232072.00
Market cap
$239.53M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.5x
P/E (TTM)
—
RSI (14)
45.7
MomentumView details →
1D Return
+11.78%
YTD Return
−45.49%
SummaryUpdated Jun 1, 2026
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is a medical device and immunotherapy company founded in 2017 and based in Westminster, Colorado. The company went public in February 2021 and specializes in developing innovative treatment technologies for liver and pancreatic cancers. TriSalus has established itself as a pioneer in pressure-enabled drug delivery (PEDD) technology, which allows for more targeted and effective treatment of solid tumors through specialized infusion systems.
Similar companies
Latest newsMore news →
TriSalus Life Sciences announced that it will host a conference call and webcast on November 10, 2026, to discuss financial results for the quarter ended September 30, 2026.15d agoTriSalus Life Sciences received U.S. FDA 510(k) clearance for its TriNav Advance device, expanding its Pressure-Enabled Drug Delivery portfolio for liver embolization.43d ago